Regression of an ALK-Negative Cerebral Inflammatory Myofibroblastic Tumour by Steroid Therapy: A Case Report and Literature Review
DOI:
https://doi.org/10.62382/jcbt.v1i1.5Keywords:
Inflammatory myofibroblastic tumours, Central nervous system, Steroid therapy, ALK rearrangement, Cerebral tumoursAbstract
Introduction: Inflammatory myofibroblastic tumours (IMTs) are non-neoplastic lesions characterized by collagenous stroma and polyclonal mononuclear infiltrates. IMTs typically arise in the lung, retroperitoneum or abdominal region but rarely in the central nervous system (CNS). The primary therapeutic option is surgical resection, and other therapies are currently controversial. Case report: We report a case of 23-year-old male ALK-negative cerebral IMT patient from Han population via steroid therapy. No relapse is observed at the follow-up visit. Conclusion: These results support the role of internal medication and promote the use of personalized therapy in genome-profiled IMTs.
Downloads
References
Hausler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, et al. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Human Pathology. 2003, 34, 253-262. DOI: 10.1053/hupa.2003.35.
Surabhi VR, Chua S, Patel RP, Takahashi N, Lalwani N, et al. Inflammatory Myofibroblastic Tumors: Current Update. Radiologic Clinics of North America. 2016, 54, 553-563. DOI: 10.1016/j.rcl.2015.12.005.
Rich BS, Fishbein J, Lautz T, Rubalcava NS, Kartal T, et al. Inflammatory myofibroblastic tumor: A multi-institutional study from the Pediatric Surgical Oncology Research Collaborative. International Journal of Cancer. 2022, 151, 1059-1067. DOI: 10.1002/ijc.34132.
Derrey S, Charpentier C, Gerardin E, Langlois O, Touchais JY, et al. Inflammatory pseudotumor of the cerebellum in a patient with Crohn's disease. World Neurosurgery. 2012, 77(01), 201, e213-206. DOI: 10.1016/j.wneu.2011.05.034.
S al-Sarraj, J Wasserberg, R Bartlett, LR Bridges. Inflammatory pseudotumour of the central nervous system: clinicopathological study of one case and review of the literature. British Journal of Neurosurgery 1995, 9, 57-66. DOI: 10.1080/02688699550041764.
Fletcher CD. The evolving classification of soft tissue tumours-an update based on the new 2013 WHO classification. Histopathology. 2014, 64, 2-11. DOI: 10.1111/his.12267.
Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? Journal of Clinical Pathology. 2008, 61, 428-437. DOI: 10.1136/jcp.2007.049387.
Dettmeyer R, Varchmin-Schultheiss K, Madea B. Intracranial plasma cell granuloma and homocystinuria. Pathology, Research and Practice. 1998, 194, 205-208. DOI: 10.1016/S0344-0338(98)80025-3.
Lui PC, Fan YS, Wong SS, Chan ANH, Wong G, et al. Inflammatory pseudotumors of the central nervous system. Human Pathology. 2009, 40, 1611-1617. DOI: 10.1016/j.humpath.2009.04.016.
Kim SA, Lee SR, Huh J, Shen SS, Ro JY. IgG4-associated inflammatory pseudotumor of ureter: clinicopathologic and immunohistochemical study of 3 cases. Human Pathology. 2011, 42, 1178-1184. DOI: 10.1016/j.humpath.2010.03.011.
Wang X, Chen Y, Wu X, Zhang HL. Intracranial Inflammatory Myofibroblastic Tumor with Negative Expression of Anaplastic Lymphoma Kinase: A Case Report and Review of the Literature. World Neurosurgery. 2019, 125, 117-122. 2019/02/09. DOI: 10.1016/j.wneu.2019.01.155.
Carswell C, Chataway J. The successful long-term management of an intracranial inflammatory myofibroblastic tumor with corticosteroids. Clinical Neurology and Neurosurgery. 2012, 114, 77-79. 2011/09/06. DOI: 10.1016/j.clineuro.2011.07.026.
Yi E, Aubry MC. Pulmonary pseudoneoplasms. Archives of Pathology & Laboratory Medicine. 2010, 134, 417-426. DOI: 10.1043/1543-2165-134.3.417.
Moss HE, Mejico LJ, de la Roza G, Coyne TM, Galetta SL, et al. IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. Journal of the Neurological Sciences. 2012, 318, 31-35. DOI: 10.1016/j.jns.2012.04.010.
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Modern Pathology. 2001, 14, 569-576. DOI: 10.1038/modpathol.3880352.
Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Research. 1999, 59, 2776-2780. PMID: 10383129.
Chang JC, Zhang L, Drilon AE, Chi P, Alaggio R, et al. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. Journal of Thoracic Oncology. 2019, 14, 825-834. DOI: 10.1016/j.jtho.2018.12.003.
Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discovery. 2014, 4, 889-895. DOI: 10.1158/2159-8290.CD-14-0377.
Dai Y, Wei Q, Schwager C, Moustafa M, Zhou C, et al. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Radiotherapy and Oncology. 2015, 114, 173-181. DOI: 10.1016/j.radonc.2014.12.009.
Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biology & Therapy. 2007, 6, 1318-1323.
Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. The New England Journal of Medicine. 2010, 363, 1727-1733. DOI: 10.1056/NEJMoa1007056.
Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang HQ, et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. American Journal of Hematology. 2018, 93, 607-614. DOI: 10.1002/ajh.25043.
Schoffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. The Lancet Respiratory Medicine. 2018, 6, 431-441. DOI: 10.1016/S2213-2600(18)30116-4.
Watanabe R, Ano S, Kikuchi N, Shigemasa R, Kondo Y, et al. Inflammatory myofibroblastic tumor directly invading the right first rib treated with oral steroids: a case report. BMC Pulmonary Medicine. 2024, 24, 67. DOI: 10.1186/s12890-024-02873-6.
Jiang JY, Comsa M, Wong VCK, Mansberg R. Steroid responsive inflammatory myofibroblastic tumor of the lung evaluated by FDG PET/CT imaging. Radiology Case Reports. 2022, 17, 907-910. DOI: 10.1016/j.radcr.2021.11.049.
Gros L, Dei Tos AP, Jones RL, Digklia A. Inflammatory Myofibroblastic Tumour: State of the Art. Cancers (Basel). 2022, 14. DOI: 10.3390/cancers14153662.
Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Research. 2005, 65, 3643-3655. DOI: 10.1158/0008-5472.CAN-04-1668.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Cancer Biomoleculars and Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
